pCDNA3.1-FLAG-SF3B1-WT Citations (10)
Originally described in: Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.Kesarwani AK, Ramirez O, Gupta AK, Yang X, Murthy T, Minella AC, Pillai MM Oncogene. 2016 Aug 15. doi: 10.1038/onc.2016.279. PubMed Journal
Articles Citing pCDNA3.1-FLAG-SF3B1-WT
| Articles |
|---|
| A substrate-trapping strategy for protein phosphatase PP1 holoenzymes using hypoactive subunit fusions. Wu D, De Wever V, Derua R, Winkler C, Beullens M, Van Eynde A, Bollen M. J Biol Chem. 2018 Sep 28;293(39):15152-15162. doi: 10.1074/jbc.RA118.004132. Epub 2018 Aug 16. PubMed |
Degenerate minigene library analysis enables identification of altered branch point utilization by mutant splicing factor 3B1 (SF3B1).
Gupta AK, Murthy T, Paul KV, Ramirez O, Fisher JB, Rao S, Rosenberg AB, Seelig G, Minella AC, Pillai MM.
Nucleic Acids Res. 2018 Nov 20. pii: 5193340. doi: 10.1093/nar/gky1161.
PubMed
Associated Plasmids |
| PCBP1 inhibits the expression of oncogenic STAT3 isoform by targeting alternative splicing of STAT3 exon 23. Wang X, Guo J, Che X, Jia R. Int J Biol Sci. 2019 May 7;15(6):1177-1186. doi: 10.7150/ijbs.33103. eCollection 2019. PubMed |
| Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription. Rimel JK, Poss ZC, Erickson B, Maas ZL, Ebmeier CC, Johnson JL, Decker TM, Yaron TM, Bradley MJ, Hamman KB, Hu S, Malojcic G, Marineau JJ, White PW, Brault M, Tao L, DeRoy P, Clavette C, Nayak S, Damon LJ, Kaltheuner IH, Bunch H, Cantley LC, Geyer M, Iwasa J, Dowell RD, Bentley DL, Old WM, Taatjes DJ. Genes Dev. 2020 Nov 1;34(21-22):1452-1473. doi: 10.1101/gad.341545.120. Epub 2020 Oct 15. PubMed |
| U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing. Choi N, Liu Y, Oh J, Ha J, Zheng X, Shen H. Cells. 2020 Dec 9;9(12). pii: cells9122647. doi: 10.3390/cells9122647. PubMed |
| SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. Simmler P, Cortijo C, Koch LM, Galliker P, Angori S, Bolck HA, Mueller C, Vukolic A, Mirtschink P, Christinat Y, Davidson NR, Lehmann KV, Pellegrini G, Pauli C, Lenggenhager D, Guccini I, Ringel T, Hirt C, Marquart KF, Schaefer M, Ratsch G, Peter M, Moch H, Stoffel M, Schwank G. Cell Rep. 2022 Aug 23;40(8):111266. doi: 10.1016/j.celrep.2022.111266. PubMed |
| Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome. Ochi T, Fujiwara T, Ono K, Suzuki C, Nikaido M, Inoue D, Kato H, Onodera K, Ichikawa S, Fukuhara N, Onishi Y, Yokoyama H, Nakamura Y, Harigae H. Sci Rep. 2022 Aug 26;12(1):14562. doi: 10.1038/s41598-022-18921-2. PubMed |
| CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1. Hluchy M, Gajduskova P, Ruiz de Los Mozos I, Rajecky M, Kluge M, Berger BT, Slaba Z, Potesil D, Weiss E, Ule J, Zdrahal Z, Knapp S, Paruch K, Friedel CC, Blazek D. Nature. 2022 Sep;609(7928):829-834. doi: 10.1038/s41586-022-05204-z. Epub 2022 Sep 14. PubMed |
| The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts. Choi IY, Ling J, Zhang J, Helmenstine E, Walter W, Bergman R, Philippe C, Manley J, Rouault-Pierre K, Li B, Wiseman D, Ouseph M, Bernard E, Li X, Haferlach T, Fazal S, Jain T, Gocke C, DeZern A, Dalton WB. Res Sq. 2023 Apr 14:rs.3.rs-2802265. doi: 10.21203/rs.3.rs-2802265/v1. Preprint. PubMed |
| Mutant SF3B1 promotes malignancy in PDAC. Simmler P, Ioannidi EI, Mengis T, Marquart KF, Asawa S, Van-Lehmann K, Kahles A, Thomas T, Schwerdel C, Aceto N, Ratsch G, Stoffel M, Schwank G. Elife. 2023 Oct 12;12:e80683. doi: 10.7554/eLife.80683. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.